Loading...

XNCR XENCOR INC Other Situations 8-K Filing

XNCR

XNCR

XENCOR INC

(XNCR)

2025 8-K

Termination Notice

Royalty Dispute

Financial Results Announcement

Financial Update

Financial Results Released

Clinical Study Update

Financial Statements

Appointing Directors

Clinical Updates

Director Appointment

Financial Results

Financial Restatement

Financial Update

Q3 Financial Results

Public Offering

Clinical Updates

Results of Operations and F...

Annual Meeting of Stockholders

Earnings Report

Resignation and Appointment...

Results of Operations and F...

Collaboration Agreement wit...

Results of Operations and F...

Departure of CFO

Appointment of Director

Results of Operations and F...

Annual Meeting of Stockholders

Results of Operations and F...

Resignation and Appointment

Regulation FD Disclosure

Sales Agreement

Results of Operations and F...

External Links:

On October 24, 2025, Xencor Inc. reported initial results from its Phase 1 clinical studies of XmAb819 and XmAb541, sharing related near-term timelines and presentations available on their website.

AI Assistant

XENCOR INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.